Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Inclusion Criteria: * A prospective patient for allogeneic HSCT for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration * The donor and recipient must have a human leukocyte antigen (HLA)-8/8 allelic match at the HLA-A, -B, -C, and -DRB1; high-resolution typing is required for all alleles * Diagnoses to be included: * Acute myelogenous leukemia at the following stages: * First remission * Second or subsequent remission * Complete remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment and \< 5% blasts in the bone marrow * Chronic myelogenous leukemia at the following stages: * First or subsequent chronic phase: * Patient refused tyrosine kinase therapy or is otherwise not suited for it * Stable, not hematologic remission: blasts present in marrow and/or peripheral blood, but disease does not qualify as accelerated or blast phase * Hematologic remission: no blast cells or precursor cells in the blood or marrow * Partial cytogenetic remission: Philadelphia chromosome positive (Ph+) metaphases \> 0% but \< 35% * Complete cytogenetic remission: absence of Ph+ metaphases * Accelerated phase - any one of the following symptoms: * White blood cells (WBC) difficult to control (\> 50 x 10\^9/L despite…